Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boundless Bio, Inc. - Common Stock (NQ:BOLD)

2.650 +0.080 (+3.11%)
Delayed Quote Updated: 1:07 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Boundless Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
From Callio Therapeutics
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether DAN, ESI, NUVL, BOLD are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Element Solutions Inc. (NYSE – ESI), Boundless Bio Inc. (Nasdaq – BOLD), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
From Boundless Bio, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
News headline image
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers 
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Leerink Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Portfolio Prioritization and Runway Extension
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Leerink Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - 
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Pipeline and Leadership Updates
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.